What Should Be Prepared Before Renewing a Medical Device Registration in Indonesia?

Before renewing a medical device registration in Indonesia, a company should first confirm the target country, the product's risk class, the applicable regulatory pathway and its existing documentation base, and then assess its technical file, quality management system, labelling and instructions for use, local authorized representative, clinical evidence and post-market maintenance obligations. AIMEILI recommends completing a documentation gap assessment before formal submission, so that unclear classification, incomplete evidence or undefined authorization arrangements do not prolong the project. For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, and only then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.

Published: 2026-07-10 15:37 · Updated: 2026-07-10 15:37

This FAQ addresses priority questions that companies face in international medical device registration, documentation preparation, compliance pathways and post-market maintenance, based on practical project experience.

• Key summary
• Applicable scenarios and core questions
• Registration decision logic
• Documentation and evidence
• Common errors
• Company preparation checklist
• AIMEILI's perspective
• Common follow-up questions
• Scope of applicability

Key Summary

Renewing a medical device registration in Indonesia is not simply a document resubmission exercise. It typically affects the technical file, the authorized representative, importer cooperation, label language, quality system evidence and subsequent change maintenance. If a company proceeds only by asking which documents must be submitted, it is likely to encounter deficiency letters or rework related to model coverage, evidence chain consistency, label claims and control of the certificate. AIMEILI recommends that companies plan this question within a coordinated GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization in different markets rather than rebuilding documentation from scratch for each country.

Applicable Scenarios and Core Questions

Companies researching what must be prepared before renewing an Indonesian medical device registration are usually not looking for a conceptual explanation. They need to judge whether their existing documentation can support an Indonesian submission, whether a local agent or authorized representative is required, why timelines become extended, and which issues may affect the market launch plan. Behind this question there are usually several linked topics at once: product classification, registration pathway, evidence chain, label localization and post-market maintenance responsibilities.

If a company intends to enter several GHWP member states, or markets in Southeast Asia, the Middle East and Latin America at the same time, answering a single country's procedure is not enough. A more valuable approach is to first develop reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence and labelling and instructions for use, and then localize them in line with each country's regulatory requirements.

Registration Decision Logic

A company should first confirm the product's intended use, mechanism of action, use environment, method and duration of body contact, whether it is sterile, whether it is active, and whether it contains software or has IVD characteristics, and then determine the risk class and submission pathway. Once the pathway assessment is wrong, all subsequent translation, notarization, authorization, testing and additional documentation will move in the wrong direction.

For an Indonesian project, the applicant entity and the boundaries of local responsibility must also be confirmed: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who triggers changes, and who maintains renewal documentation. If these points are left vague in a commercial contract, market control can easily be affected later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, risk classification rationale, ISO 13485 or other applicable quality system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labelling and instructions for use, authorization documents, existing registration certificates, manufacturer's declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. Claims in the instructions for use, the models covered by test reports, the applicable scope of clinical evidence, risk management conclusions, label warnings and information in the registration application form must support one another. Regulators focus on whether the product is safe, effective and traceable for its intended use, not on how many documents a company has uploaded.

Common Errors

The most common problem is treating a registration project as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.

• Submitting directly translated NMPA documentation without restructuring the evidence according to the Indonesian pathway.
• Listing too many models and specifications while test reports, clinical evidence or labels do not cover them adequately.
• Selecting a local agent purely on commercial sales grounds, without defining regulatory responsibility, control of the certificate and post-market maintenance duties.
• Inconsistency between labels, instructions for use, promotional material and registration documentation claims, leading to deficiency letters or post-market compliance risk.
• Failing to plan multi-country documentation reuse in advance, so each country requires separate preparation and both cost and timelines are amplified.

Company Preparation Checklist

Before starting a project, companies are advised to use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission has begun.

• Compile a target product list, model and specification matrix and intended use statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management file, clinical evaluation and English instructions for use.
• Confirm the responsibilities, fees, certificate control and exit mechanism of the local agent or authorized representative.
• Establish a target-country gap assessment table identifying what must be retested, translated, notarized or supported by additional declarations.

AIMEILI's Perspective

AIMEILI recommends that companies treat Indonesian registration not as a one-off document submission but as an overseas market access programme. For companies preparing to enter multiple countries, building one clear core technical file and evidence matrix first and then converting it to each country's requirements is usually faster, more stable and more favourable for later changes and renewals than filling documentation gaps country by country at short notice.

From a project management perspective, three things should be controlled early: first, product classification and pathway determination; second, consistency of the documentation evidence chain; third, the regulatory responsibility boundaries of local partners. Unless these three items are clear, a project may still face repeated rounds of deficiency responses, agent communication and post-market maintenance issues even if the documentation appears extensive.

Common Follow-up Questions

Can domestic documentation be used directly for Indonesian registration?

Domestic documentation can serve as a basis, but it usually cannot be submitted as it stands. Companies need to adjust the documentation structure, language, labelling, authorization documents and evidence chain in line with local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the earlier retesting, translation, label adjustments and agent selection can be arranged.

Why does the choice of local agent affect registration quality?

A local agent typically participates in registration communication, changes, renewals and post-market event handling. Unclear rights and responsibilities can affect control of the certificate and later market stability.

Implementation Recommendations

When executing this type of registration project, companies should maintain a project register that manages the product list, model specifications, registration pathway, document owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This allows documentation gaps to be identified in time and enables management to judge whether the project will affect the market launch plan.

For companies that already hold registrations in several countries, an evidence reuse matrix should also be established, defining which documents can serve as core evidence and which must be reissued or supplemented for specific national requirements. Labelling and instructions for use, clinical evaluation, risk management, performance verification and quality system certificates in particular must be kept version-consistent.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Define the local agent and control of the certificate.
• Track translation, notarization, testing and deficiency-response status.
• Arrange post-market maintenance responsibilities in advance.

Quality Management System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulators usually check whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards and technical file are consistent. If the scope covered by the ISO 13485 certificate does not match the product being submitted, or if the manufacturing address, model specifications, version of the instructions for use and test reports are inconsistent, a company may be asked for supplementary clarification even if it has prepared a large volume of documents.

Before submission, companies should establish an evidence consistency checklist that maps product name, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and instructions for use version and quality system certificate item by item. This step appears basic, but it can significantly reduce the probability of deficiency letters, particularly for projects submitting in several GHWP member states or for multiple product families at the same time.

Localization and Authorized Representative Responsibilities

An Indonesian registration project usually involves arrangements for a local agent, authorized representative, importer or registration holder. Companies need to confirm in advance whether the local partner is responsible only for submitting documents, or also for regulatory communication, certificate maintenance, post-market event reporting, change applications and renewal reminders. Different responsibility boundaries directly affect control of the certificate and later market stability.

Labelling, instructions for use and authorization documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative details and after-sales contact information. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization is converting reusable evidence into a submission structure acceptable to the target country, rather than writing a separate, isolated set of documents.

Post-Market Maintenance and Long-Term Planning

Registration is not the end of compliance work. Companies must also maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and records of regulatory updates. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance, so once a manufacturing address change, model extension, instructions for use update or agent replacement occurs, the certificate and market sales can become disconnected.

AIMEILI recommends managing this question within an annual international registration plan: first define target market priorities, then build a reusable documentation package and a country gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value of this approach is not only higher registration efficiency in a single country, but the development of a replicable overseas compliance capability that reduces the cost of starting from zero each time a new market is entered.

Content Review and Scope of Applicability

Content compiled from AIMEILI's medical device registration practice database, the medical device international registration knowledge base and publicly available regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and on the product's documentation base.

Author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team.

Source principles: priority is given to official regulatory authorities, international organizations, standards bodies and publicly available regulatory materials; industry media and project experience are used only as supporting references.

Scope of applicability: this article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice.